Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pre-“Complete Response” Deficiency Communication Possible For ANDA Sponsors

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and GPhA nearing agreement that would let generic drug sponsors receive a list of major application deficiencies before the agency issues its “complete response” letter.

You may also be interested in...



FDA/Generic Communications Plan Restoring Best Of Past Practices

Office of Generic Drugs wants to allow project managers to inform sponsors of major deficiencies before ‘complete response’ letter as part of ‘go/no go’ effort.

FDA Again Taps Compliance Director For Globalization Post

Howard Sklamberg, currently director of the CDER Office of Compliance, will take over the Office of Global Regulatory Operations and Policy after a year as CDER compliance office director.

FDA Could Release GMP Data To Prod Manufacturing Improvements

Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel